Related Experiment Video
Updated: Mar 30, 2026

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
A Single-Center Analysis of Methylprednisolone Use during Pediatric Cardiopulmonary Bypass
Molly Dreher1, Andrew C Glatz1, Andrea Kennedy1
1The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Insights
Eliminating methylprednisolone from cardiopulmonary bypass (CPB) prime did not improve outcomes in pediatric cardiac surgery patients. Steroid use was linked to increased wound infections and respiratory failure, prompting its continued exclusion from CPB prime.
Area of Science:
- Pediatric Cardiac Surgery
- Cardiopulmonary Bypass (CPB)
- Inflammatory Response
Background:
- Cardiopulmonary bypass (CPB) can trigger an inflammatory response, potentially more severe in pediatric patients.
- Corticosteroids are sometimes used in CPB prime to mitigate this response, but their effectiveness and risks are debated.
- Methylprednisolone use in CPB prime was evaluated due to recent controversies.
Purpose of the Study:
- To assess the clinical effectiveness and safety of methylprednisolone in the CPB prime for pediatric cardiac surgery.
- To determine if eliminating methylprednisolone from CPB prime impacts patient outcomes.
Main Methods:
- A quality improvement project was conducted at The Children's Hospital of Philadelphia.
- Methylprednisolone was removed from the CPB prime for a 6-month period.
- Clinical outcomes of 222 patients (post-elimination) were compared to 303 patients (pre-elimination) using The Society of Thoracic Surgeons Congenital Heart Surgery Database.
Main Results:
- No significant clinical benefit was observed in patients who received methylprednisolone in the CPB prime.
- Patients receiving methylprednisolone showed a significantly higher incidence of postoperative wound infection (p = .037) and respiratory failure requiring tracheostomy (p = .035).
- No significant differences in outcomes were found in neonates, regardless of steroid exposure.
Conclusions:
- Methylprednisolone in CPB prime offers no discernible clinical benefit for pediatric cardiac surgery patients.
- The use of methylprednisolone in CPB prime may increase the risk of wound infections and respiratory complications.
- The institution continues to exclude methylprednisolone from CPB prime, while still allowing its intraoperative use as indicated.
Abstract:
Cardiac surgery with the use of cardiopulmonary bypass (CPB) is known to induce an inflammatory response in patients. This response may be even more pronounced in pediatric patients given their small body size compared to adults. Several interventions have been instituted in an effort to attenuate this response, including the use of corticosteroids in the pump prime. However, the clinical effectiveness and potential harmful effects of steroid use have been the source of recent debate. Therefore, our institution made the decision to evaluate the use of methylprednisolone in our CPB prime. This evaluation was performed as a formal quality improvement project at The Children's Hospital of Philadelphia. Methylprednisolone was eliminated from the CPB prime for 6 months. At the end of this time period, The Society of Thoracic Surgeons Congenital Heart Surgery Database was used to evaluate clinical outcomes of patients (n = 222). These outcomes were then compared to patients operated on during the 6 months prior to elimination of methylprednisolone (n = 303). No significant clinical benefit was identified in the group of patients who received methylprednisolone. When compared to the group who did not receive methylprednisolone, significantly more patients in the steroids group had a postoperative wound infection (p = .037) or respiratory failure requiring tracheostomy ( p = .035). No other differences in clinical outcomes were identified between the two groups. No significant differences in clinical outcomes were identified between neonates who received methylprednisolone (n = 55) and neonates who did not receive steroids (n = 58). Due to the lack of clinical benefit seen with its use, as well as its potential contribution to the incidence of wound infection, methylprednisolone continues to be excluded from the CPB prime at our institution. Methylprednisolone is still given intraoperatively at the request of the attending anesthesiologist and on bypass during orthotopic transplant procedures according to institutional protocol.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
COPD: Management Using Bronchodilators and Corticosteroids
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Myocarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Depolarizing Blockers: Pharmocokinetics

